{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:22:32Z","timestamp":1781763752482,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.pcad.2024.08.004","type":"journal-article","created":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T13:52:52Z","timestamp":1724593972000},"page":"54-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The prevalence, patients' characteristics, and hyper-Lp(a)-emia risk factors in the Polish population. The first results from the PMMHRI-Lp(a) Registry"],"prefix":"10.1016","volume":"86","author":[{"given":"Bo\u017cena","family":"Sosnowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Lewek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"Adach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Mierczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Bielecka-D\u0105browa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Szosland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiusz","family":"Zygmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"D\u0105browski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.pcad.2024.08.004_bb0005","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pcad.2024.08.004_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.pcad.2024.08.004_bb0015","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein(a), and cardiovascular risk thresholds","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"39","key":"10.1016\/j.pcad.2024.08.004_bb0020","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.pcad.2024.08.004_bb0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5114\/aoms\/183522","article-title":"Recommendations of the experts of the polish cardiac society (PCS) and the polish lipid association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels","volume":"20","author":"Sosnowska","year":"2024","journal-title":"Arch Med Sci"},{"issue":"6","key":"10.1016\/j.pcad.2024.08.004_bb0030","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.5114\/aoms\/141941","article-title":"PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021","volume":"17","author":"Banach","year":"2021","journal-title":"Arch Med Sci"},{"issue":"18","key":"10.1016\/j.pcad.2024.08.004_bb0035","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031255","article-title":"Lipoprotein(a) testing trends in a large academic health system in the United States","volume":"12","author":"Bhatia","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.pcad.2024.08.004_bb0040","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1093\/eurjpc\/zwae155","article-title":"Trends and disparities in lipoprotein(a) testing in a large integrated US health system, 2000\u201323","volume":"31","author":"Faaborg-Andersen","year":"2024","journal-title":"Eur. J Prev Cardiol."},{"key":"10.1016\/j.pcad.2024.08.004_bb0045","doi-asserted-by":"crossref","DOI":"10.1007\/s00392-024-02427-0","article-title":"on behalf of the MEDIAN Medical Board Cardiology. Prevalence of elevated lipoprotein(a) in cardiac rehabilitation patients \u2014 results from a large-scale multicentre registry in Germany","author":"Altmann","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.pcad.2024.08.004_bb0050","article-title":"Monitoring of traditional atherosclerosis cardiovascular disease risk factors - is it enough to prevent premature acute coronary syndrome?","volume":"38","author":"Banach","year":"2024","journal-title":"Lancet Reg Health - Eur"},{"issue":"25","key":"10.1016\/j.pcad.2024.08.004_bb0055","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global burden of cardiovascular diseases and risks, 1990-2022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.pcad.2024.08.004_bb0060","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"issue":"S1","key":"10.1016\/j.pcad.2024.08.004_bb0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11789-017-0087-y","article-title":"Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease","volume":"12","author":"Van Buuren","year":"2017","journal-title":"Clin Res Cardiol Suppl"},{"issue":"12","key":"10.1016\/j.pcad.2024.08.004_bb0070","first-page":"1279","article-title":"Elevated lipoprotein (a) in middle-aged polish population: preliminary data on genetic background","volume":"81","author":"Konieczy\u0144ska","year":"2023","journal-title":"Kardiol Pol"},{"issue":"4","key":"10.1016\/j.pcad.2024.08.004_bb0075","doi-asserted-by":"crossref","DOI":"10.5114\/aoms\/188294","article-title":"Lipoprotein(a) and its impact on cardiovascular disease \u2013 the polish perspective: design, and first results of the Zabrze-lipoprotein(a) registry","volume":"20","author":"Dyrbu\u015b","year":"2024","journal-title":"Arch Med Sci"},{"issue":"11","key":"10.1016\/j.pcad.2024.08.004_bb0080","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/metabo12111065","article-title":"Familial hypercholesterolemia and lipoprotein(a): a Gordian knot in cardiovascular prevention","volume":"12","author":"Koutsogianni","year":"2022","journal-title":"Metabolites"},{"issue":"19","key":"10.1016\/j.pcad.2024.08.004_bb0085","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2024.08.004_bb0090","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12944-020-01289-5","article-title":"Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry","volume":"19","author":"Rizos","year":"2020","journal-title":"Lipids Health Dis"},{"issue":"12","key":"10.1016\/j.pcad.2024.08.004_bb0095","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1210\/clinem\/dgaa672","article-title":"Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis","volume":"105","author":"Kotwal","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.pcad.2024.08.004_bb0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.mcna.2012.01.012","article-title":"The effect of thyroid disorders on lipid levels and metabolism","volume":"96","author":"Duntas","year":"2012","journal-title":"Med Clin North Am"},{"issue":"9","key":"10.1016\/j.pcad.2024.08.004_bb0105","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1515\/CCLM.1998.129","article-title":"Effect of thyroid hormones on Lp(a) and lipid metabolism","volume":"36","author":"Engler","year":"1998","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"10.1016\/j.pcad.2024.08.004_bb0110","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J Clin Invest"},{"issue":"47","key":"10.1016\/j.pcad.2024.08.004_bb0115","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1093\/eurheartj\/ehad635","article-title":"Banach M, endorsed by the international lipid expert panel (ILEP). Low carbohydrate\/ketogenic diet in the optimization of lipoprotein(a) levels: do we have sufficient evidence for any recommendation?","volume":"44","author":"Surma","year":"2023","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.pcad.2024.08.004_bb0120","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.5114\/aoms\/187774","article-title":"Association between Lp(a) and T2D: a Mendelian randomization study","volume":"20","author":"Go\u0142awski","year":"2024","journal-title":"Arch Med Sci"},{"issue":"4","key":"10.1016\/j.pcad.2024.08.004_bb0125","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead080","article-title":"Lipoprotein(a): the enemy that we still don\u2019t know how to defeat","volume":"3","author":"Banach","year":"2023","journal-title":"Eur Heart J Open"},{"issue":"11","key":"10.1016\/j.pcad.2024.08.004_bb0130","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/aje\/kwp043","article-title":"Lipid changes during the menopause transition in relation to age and weight: the study of Women\u2019s health across the nation","volume":"169","author":"Derby","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.pcad.2024.08.004_bb0135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajcnut.2023.05.017","article-title":"Lipoprotein(a) and diet\u2014a challenge for a role of saturated fat in cardiovascular disease risk reduction?","volume":"118","author":"Law","year":"2023","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.pcad.2024.08.004_bb0140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"issue":"Suppl_1","key":"10.1016\/j.pcad.2024.08.004_bb0145","first-page":"148","article-title":"Abstract 12103: Intraindividual variability in serial lipoprotein(a) concentration among placebo-treated patients in the OCEAN(a)-DOSE trial","author":"Gaba","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.pcad.2024.08.004_bb0150","doi-asserted-by":"crossref","first-page":"556","DOI":"10.21037\/atm-20-5324","article-title":"Visit-to-visit variability of lipid and cardiovascular events in patients with familial hypercholesterolemia","volume":"9","author":"Cao","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.pcad.2024.08.004_bb0155","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pcad.2023.07.006","article-title":"Lipoprotein(a) in clinical practice: a guide for the clinician","volume":"79","author":"Krittanawong","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"issue":"12","key":"10.1016\/j.pcad.2024.08.004_bb0160","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3390\/ph15121573","article-title":"Targeted treatment against lipoprotein (a): the coming breakthrough in lipid lowering therapy","volume":"15","author":"Sosnowska","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.pcad.2024.08.004_bb0165","first-page":"27","article-title":"All we need to know about lipoprotein(a)","volume":"84","author":"Bess","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"10.1016\/j.pcad.2024.08.004_bb0170","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","article-title":"Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"Awad","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.pcad.2024.08.004_bb0175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pcad.2022.01.002","article-title":"Global think tank on the clinical considerations and management of lipoprotein(a): the top questions and answers regarding what clinicians need to know","volume":"73","author":"Virani","year":"2022","journal-title":"Prog Cardiovasc Dis"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062024001154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062024001154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T22:11:44Z","timestamp":1738188704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062024001154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":35,"alternative-id":["S0033062024001154"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2024.08.004","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prevalence, patients' characteristics, and hyper-Lp(a)-emia risk factors in the Polish population. The first results from the PMMHRI-Lp(a) Registry","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2024.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}